Bionovate Technologies picks up semanticom for international PR

Rhea-AI Summary

Bionovate Technologies Corp., focused on digital transformation in healthcare, has partnered with semanticom for international PR and communications. The company is developing an FDA-approved ecosystem of mobile health diagnostics, transforming lab tests into smartphone-compatible versions. Recently, Bionovate acquired shares in Digital Diagnostics AG, which is launching a rapid corona antigen test soon. This strategic move aligns with their goal to innovate within the high-growth medical device market.

Positive

• Partnership with semanticom enhances international PR and corporate communications.
• Acquisition of shares in Digital Diagnostics AG positions Bionovate to benefit from the launch of a rapid corona antigen test.
• Focus on FDA-approved mobile diagnostics aligns with high-growth opportunities in the medical device sector.

Negative

• None.

CHAM, Switzerland and BERLIN, Oct. 17, 2020 (GLOBE NEWSWIRE) -- The Berlin public relations agency wins the business with international PR and strategic corporate communications of the medical device company Bionovate Technologies Corp. The shares of the company are traded on the Nasdaq OTC (OTCPK:BIIO).

Bionovate Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an FDA-approved ecosystem of medical devices, biosensors and mobile applications to turn tests that were previously only done in physical labs into tests that can be carried through by anyone with a mobile device. Innovations in these fields are transforming some of the most promising, high-growth-opportunity segments in the medical device market worldwide.

Thanks to a recently executed agreement, Bionovate will hold shares in the German health tech start up Digital Diagnostics AG, which is currently developing a promising rapid corona antigen test and will shortly launch it to the markets.

Aleksandar Vucak, CEO of Bionovate: "semanticom has recognized expertise in the positioning and popular explanation of new technologies and has broad experience in international public relations for start-ups. That's why we chose the Berlin agency."

Bionovate Technologies Corp.
Gewerbestr. 10
6330 Cham, Switzerland

press contact
Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
bionovate-pr@semanticom.eu

FAQ

What is the recent partnership of Bionovate Technologies Corp. about?

Bionovate has partnered with semanticom for international PR and strategic communications.

What market is Bionovate Technologies Corp. targeting?

Bionovate is targeting the mobile healthcare diagnostics market, aiming to create an FDA-approved ecosystem.

What recent acquisition did Bionovate Technologies Corp. make?

Bionovate recently acquired shares in Digital Diagnostics AG, which is developing a rapid corona antigen test.

How does Bionovate Technologies Corp. aim to innovate in healthcare?

Bionovate aims to transform lab tests into mobile-compatible tests, enhancing accessibility to healthcare diagnostics.